Form 4: ResMed CEO Michael Farrell Exercises, Sells Shares

ResMed Chairman and CEO Michael J. Farrell exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc., engaged in transactions involving the company's common stock on November 7, 2025.
• He acquired a total of 8,011 shares of ResMed Common Stock through the exercise of options at a price of $101.64 per share.
• Simultaneously, he disposed of 8,011 shares of ResMed Common Stock at a weighted average sale price of $249.7532 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 plan adopted on October 31, 2024.
• The reported direct beneficial ownership of ResMed Common Stock following these transactions is 467,866 shares.
• An additional 2,090 shares are indirectly beneficially owned through the Lisette and Michael Farrell Family Trust.
• The direct beneficial ownership also includes 74.3412 shares purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions represent a common practice of exercising options and selling shares for liquidity or tax purposes, especially when conducted under a pre-arranged 10b5-1 plan. The net change in direct beneficial ownership from these specific transactions is zero, as the number of shares acquired through option exercise equals the number sold.

Positives

• The exercise of stock options indicates that the options were in-the-money, reflecting an increase in the company's stock value since the options were granted.
• The purchase of 74.3412 shares through the ResMed Employee Stock Purchase Plan demonstrates continued investment by the CEO in the company's equity.

Negatives

• The disposition of 8,011 shares by the Chairman and CEO reduces his direct equity stake, which some investors may interpret as a decrease in insider alignment, although it was part of a pre-planned strategy.

Future Outlook

NA

Management Comments

• The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024, indicating a pre-scheduled and automated trading arrangement.

Industry Context

This Form 4 filing details routine insider trading activity by a senior executive, which is common across all industries for liquidity and diversification purposes. It does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• Indirect beneficial ownership of 2,090 shares through the Lisette and Michael Farrell Family Trust.
• Purchase of 74.3412 shares through the ResMed Employee Stock Purchase Plan, a standard employee benefit.

Stakeholder Impact

• Shareholders may observe a slight reduction in the CEO's direct equity stake, which could be interpreted differently depending on individual investment philosophies, though the 10b5-1 plan mitigates concerns about opportunistic selling.
• The transactions do not directly impact employees, customers, suppliers, or creditors beyond the general market perception of insider activity.

Key Dates

Recommendation

This Form 4 filing primarily reports routine insider transactions (option exercise and sale) executed under a pre-planned 10b5-1 arrangement. While insider selling can sometimes be a negative signal, the context of a 10b5-1 plan and the equal number of shares exercised and sold suggests a liquidity or tax-related event rather than a change in management's outlook on the company's fundamentals. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis.

Keywords

ResMed, RMD, Michael J. Farrell, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO, Corporate Governance